{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for tyrosine in Related Substance Name (approximate match)
Status:
Investigational
Source:
INN:fidasimtamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:izalontamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02399137: Phase 2 Interventional Completed Pancreatic Cancer
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01479244: Phase 3 Interventional Completed Breast Cancer With Low to Intermediate HER2 Expression
(2011)
Source URL:
Class:
PROTEIN
Nelipepimut-S (formerly known as E75) is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer. The NeuVax™ (Galena, OR, USA) vaccine, nelipepimut-S plus granulocyte-macrophage colony-stimulating factor, is designed for the prevention of clinical recurrences in high risk, disease-free breast cancer patients. Nelipepimut-S is being developed by Sellas Life Sciences Group. When combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), nelipepimut-S has been used as a vaccine that is capable of eliciting a robust anti-HER2 immune response. Early-phase clinical trials that enrolled women with node-positive or high-risk node-negative breast cancer who had been rendered disease free with standard of care therapy but were at risk for recurrence, demonstrated the vaccine to be safe with a suggestion of clinical benefit. Nelipepimut-S is currently being evaluated in a Phase III clinical trial.
Status:
Investigational
Source:
NCT01652482: Phase 2 Interventional Completed Colorectal Cancer
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01042379: Phase 2 Interventional Recruiting Breast Neoplasms
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04175171: Phase 1 Interventional Completed Metastatic Breast Cancer
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03552406: Phase 1 Interventional Unknown status Solid Tumor
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tezatabep matraxetan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab vedotin [INN]
Source URL:
Class:
PROTEIN
